Estevinho MM, Rocha C, Correia L, et al. - This systematic review was undertaken to investigate connections among microbiome composition and functions (at baseline and throughout the treatment) and therapy-related outcomes to ascertain if colon or fecal microbiomes could be used as biomarkers of response to therapy. The inclusion criteria were met by 10 studies from the 787 citations identified. From patients with inflammatory bowel diseases (IBD) who responded to treatment with biologic agents, evidence for consistent changes in microbiomes of fecal and colon samples was found. After treatment with antibodies against integrins, patients in remission had reduced Roseburia abundance. Prospective studies are required to determine what changes are substantially associated with therapy, whether these modifications are causes or reaction impacts, or whether intestinal microbiome composition can be used to select treatments for IBD patients.